Edgewise Therapeutics (EWTX) to Release Earnings on Thursday

Key Points

• Edgewise Therapeutics is scheduled to report Q2 2026 results before the market opens on Thursday, August 6. Analysts expect a loss of $0.48 per share, compared with a $0.46-per-share loss reported in the prior quarter that exceeded consensus estimates.
• EWTX shares opened at $39.75, with a market capitalization of approximately $4.28 billion and a 52-week trading range of $12.30 to $48.40.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $48.75, while insiders have sold about $9.97 million in shares over the past 90 days.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Edgewise Therapeutics to post earnings of ($0.48) per share for the quarter. Parties may review the information on the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.04. On average, analysts expect Edgewise Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edgewise Therapeutics Trading Down 1.5%

Shares of EWTX opened at $39.75 on Thursday. The firm has a market capitalization of $4.28 billion, a P/E ratio of -23.95 and a beta of 0.27. Edgewise Therapeutics has a twelve month low of $12.30 and a twelve month high of $48.40. The stock's fifty day simple moving average is $38.20 and its 200 day simple moving average is $33.34.

Analyst Ratings Changes

A number of research firms recently issued reports on EWTX. The Goldman Sachs Group increased their target price on shares of Edgewise Therapeutics from $20.00 to $32.00 and gave the stock a "neutral" rating in a research report on Wednesday, June 17th. Royal Bank Of Canada increased their price objective on shares of Edgewise Therapeutics from $48.00 to $59.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 17th. Truist Financial set a $52.00 target price on shares of Edgewise Therapeutics in a research note on Wednesday, May 6th. Evercore reaffirmed an "outperform" rating and set a $55.00 price target on shares of Edgewise Therapeutics in a research report on Monday, July 20th. Finally, Raymond James Financial reiterated a "strong-buy" rating and issued a $66.00 price target on shares of Edgewise Therapeutics in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $48.75.

Insider Activity

In related news, insider Alan J. Russell sold 200,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $39.41, for a total transaction of $7,882,000.00. Following the sale, the insider owned 24,555 shares in the company, valued at $967,712.55. This represents a 89.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Joanne M. Donovan sold 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total value of $1,928,500.00. Following the completion of the sale, the chief marketing officer directly owned 4,367 shares in the company, valued at approximately $168,435.19. This trade represents a 91.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 255,230 shares of company stock valued at $9,974,147 over the last 90 days. Insiders own 21.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC lifted its holdings in shares of Edgewise Therapeutics by 23.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company's stock valued at $71,000 after buying an additional 550 shares during the period. California State Teachers Retirement System boosted its holdings in Edgewise Therapeutics by 2.4% during the second quarter. California State Teachers Retirement System now owns 36,878 shares of the company's stock worth $483,000 after buying an additional 850 shares in the last quarter. Creative Planning boosted its holdings in Edgewise Therapeutics by 6.7% during the third quarter. Creative Planning now owns 18,036 shares of the company's stock worth $293,000 after buying an additional 1,126 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Edgewise Therapeutics by 14.9% in the second quarter. Tower Research Capital LLC TRC now owns 9,148 shares of the company's stock worth $120,000 after buying an additional 1,188 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Edgewise Therapeutics by 3.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 36,759 shares of the company's stock worth $912,000 after buying an additional 1,221 shares during the last quarter.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc NASDAQ: EWTX is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.